688180 Shanghai Junshi Biosciences Co.,Ltd.
Closed 12-12 15:00:01
36.58
+0.27
+0.74%
High36.80Low35.98Vol7.78M
Open36.50D1 Closing36.31Amplitude2.26%
Mkt Cap37.57BTradable Cap28.02BTotal Shares1.03B
T/O284.00MT/O Rate1.02%Tradable Shares766.00M
P/B6.04ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

FDA Approves IND Application for Shanghai Junshi Biosciences’ JS212
Reuters  ·  18:54
FDA Approves IND Application for Shanghai Junshi Biosciences’ JS212
BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLN
Reuters  ·  12-10
BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLN
Shanghai Junshi Biosciences - Chairman Xiong Jun Intended to Increase Shareholding in a Shares and H Shares for No Less Than RMB100 Mln
THOMSON REUTERS  ·  12-10
Shanghai Junshi Biosciences - Chairman Xiong Jun Intended to Increase Shareholding in a Shares and H Shares for No Less Than RMB100 Mln
Junshi Biosciences' Application for Plaque Psoriasis Drug Gets China Approval
MT Newswires Live  ·  12-08
Junshi Biosciences' Application for Plaque Psoriasis Drug Gets China Approval
Junshi Biosciences' Four Drugs Placed on China's Insurance Drug List
MT Newswires Live  ·  12-08
Junshi Biosciences' Four Drugs Placed on China's Insurance Drug List
HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List
Stock News  ·  12-08
HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List
Shanghai Junshi Biosciences Wins NRDL Inclusion for New Indications of TUOYI and JUNSHIDA
Reuters  ·  12-07
Shanghai Junshi Biosciences Wins NRDL Inclusion for New Indications of TUOYI and JUNSHIDA
Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials
Reuters  ·  12-06
Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials
Junshi Biosciences Announces Acceptance of the Nda for Roconkibart (Il-17a) for the Treatment of Moderate to Severe Plaque Psoriasis
THOMSON REUTERS  ·  12-05
Junshi Biosciences Announces Acceptance of the Nda for Roconkibart (Il-17a) for the Treatment of Moderate to Severe Plaque Psoriasis
BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug Application
Reuters  ·  12-05
BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug Application
Shanghai Junshi Biosciences Receives Acceptance for Roconkibart Injection NDA for Plaque Psoriasis
Reuters  ·  12-05
Shanghai Junshi Biosciences Receives Acceptance for Roconkibart Injection NDA for Plaque Psoriasis
Shanghai Junshi Biosciences - Acceptance of New Drug Application for Roconkibart Injection by Nmpa
THOMSON REUTERS  ·  12-05
Shanghai Junshi Biosciences - Acceptance of New Drug Application for Roconkibart Injection by Nmpa
Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted
Stock News  ·  12-05
Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted
JUNSHI BIO (01877) Plans to Utilize Idle Raised Funds for Cash Management
Stock News  ·  11-27
JUNSHI BIO (01877) Plans to Utilize Idle Raised Funds for Cash Management
Shanghai Junshi Biosciences Board Approves Cash Management Using Temporarily Idle Proceeds
Reuters  ·  11-27
Shanghai Junshi Biosciences Board Approves Cash Management Using Temporarily Idle Proceeds
HK Stock Movement | JUNSHI BIO (01877) Rises Over 5% Again as Toripalimab Subcutaneous Injection Phase III Trial Meets Primary Endpoint, Plans Submission for Market Approval
Stock News  ·  11-26
HK Stock Movement | JUNSHI BIO (01877) Rises Over 5% Again as Toripalimab Subcutaneous Injection Phase III Trial Meets Primary Endpoint, Plans Submission for Market Approval
BUZZ-Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment
Reuters  ·  11-25
BUZZ-Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment
HK Stock Movement | JUNSHI BIO (01877) Rises Nearly 5% as JS001sc Meets Primary Endpoint in Phase III Lung Cancer Trial; Company to Submit Marketing Authorization Application Soon
Stock News  ·  11-25
HK Stock Movement | JUNSHI BIO (01877) Rises Nearly 5% as JS001sc Meets Primary Endpoint in Phase III Lung Cancer Trial; Company to Submit Marketing Authorization Application Soon
Junshi Biosciences Announces Primary Endpoints Met in Js001sc’s Phase 3 Study for the 1St-Line Treatment of Nsq-Nsclc
THOMSON REUTERS  ·  11-25
Junshi Biosciences Announces Primary Endpoints Met in Js001sc’s Phase 3 Study for the 1St-Line Treatment of Nsq-Nsclc
Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC
Reuters  ·  11-24
Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC

Introduction

Company Name.
上海君实生物医药科技股份有限公司
Industry:
医药制造业
Listing Date:
2020-07-15
Main Business:
　　上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主，同时通过合作开发、设立合资企业以及许可（license-in）等形式引进与自有源创产品线有协同作用的药物或平台技术，进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”，并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。
Issue price:
55.50